Compare Stocks: VNDA, CRON, CALT, and PCRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
CRON Cronos Group	$3.18 -2.5%	$3.02	$2.28 ▼ $3.61	$1.20B	0.94	1.31 million shs	927,991 shs
PCRX Pacira BioSciences	$25.87 -1.8%	$25.46	$18.80 ▼ $27.66	$1.05B	0.26	512,299 shs	386,421 shs
VNDA Vanda Pharmaceuticals	$5.33 -1.8%	$5.48	$4.27 ▼ $9.94	$328.31M	0.64	760,650 shs	620,645 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	0.00%
CRON Cronos Group	0.00%	-3.26%	+5.16%	+16.85%	+30.40%
PCRX Pacira BioSciences	0.00%	+1.74%	+5.32%	+13.53%	-0.38%
VNDA Vanda Pharmaceuticals	0.00%	+0.56%	+8.60%	-11.27%	+17.79%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
CRON Cronos Group	$3.18 -2.5%	$3.02	$2.28 ▼ $3.61	$1.20B	0.94	1.31 million shs	927,991 shs
PCRX Pacira BioSciences	$25.87 -1.8%	$25.46	$18.80 ▼ $27.66	$1.05B	0.26	512,299 shs	386,421 shs
VNDA Vanda Pharmaceuticals	$5.33 -1.8%	$5.48	$4.27 ▼ $9.94	$328.31M	0.64	760,650 shs	620,645 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	0.00%
CRON Cronos Group	0.00%	-3.26%	+5.16%	+16.85%	+30.40%
PCRX Pacira BioSciences	0.00%	+1.74%	+5.32%	+13.53%	-0.38%
VNDA Vanda Pharmaceuticals	0.00%	+0.56%	+8.60%	-11.27%	+17.79%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
CRON Cronos Group	2.60	Moderate Buy	$2.30	-27.67% Downside
PCRX Pacira BioSciences	2.43	Hold	$30.20	16.74% Upside
VNDA Vanda Pharmaceuticals	2.50	Moderate Buy	$13.70	157.04% Upside

Current Analyst Ratings Breakdown

Latest VNDA, CRON, CALT, and PCRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	PCRX Pacira BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
8/26/2026	CRON Cronos Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/17/2026	PCRX Pacira BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
8/17/2026	PCRX Pacira BioSciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$30.00
8/12/2026	CRON Cronos Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C+)
8/10/2026	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$21.00 ➝ $20.00
8/10/2026	VNDA Vanda Pharmaceuticals	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$17.00 ➝ $12.00
8/5/2026	PCRX Pacira BioSciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$24.00 ➝ $25.00
8/5/2026	PCRX Pacira BioSciences	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $33.00
7/17/2026	VNDA Vanda Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/1/2026	PCRX Pacira BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$38.00

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
CRON Cronos Group	$146.59M	7.99	$0.01 per share	260.03	$3.00 per share	1.06
PCRX Pacira BioSciences	$726.41M	1.42	$3.79 per share	6.83	$16.11 per share	1.61
VNDA Vanda Pharmaceuticals	$216.10M	1.49	N/A	N/A	$5.54 per share	0.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
CRON Cronos Group	-$9.45M	$0.20	15.90	N/A	N/A	39.08%	4.85%	4.62%	11/5/2026 (Estimated)
PCRX Pacira BioSciences	$7.03M	$0.35	73.92	10.78	N/A	1.96%	9.68%	5.30%	11/5/2026 (Estimated)
VNDA Vanda Pharmaceuticals	-$220.47M	-$4.63	N/A	N/A	N/A	-127.41%	-49.81%	-33.29%	11/4/2026 (Estimated)

Latest VNDA, CRON, CALT, and PCRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CRON Cronos Group	$0.01	$0.09	+$0.08	$0.09	$44.20 million	$53.01 million
8/5/2026	Q2 2026	VNDA Vanda Pharmaceuticals	-$0.5825	-$1.04	-$0.4575	-$1.04	$61.93 million	$50.53 million
8/4/2026	Q2 2026	PCRX Pacira BioSciences	$0.6460	$0.73	+$0.0840	$0.12	$191.06 million	$192.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
PCRX Pacira BioSciences	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
CRON Cronos Group	N/A	16.18	15.25
PCRX Pacira BioSciences	0.54	5.04	3.94
VNDA Vanda Pharmaceuticals	0.01	1.61	1.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALT Calliditas Therapeutics AB (publ)	2.83%
CRON Cronos Group	8.71%
PCRX Pacira BioSciences	99.73%
VNDA Vanda Pharmaceuticals	88.14%

Insider Ownership

Company	Insider Ownership
CALT Calliditas Therapeutics AB (publ)	2.20%
CRON Cronos Group	7.80%
PCRX Pacira BioSciences	6.40%
VNDA Vanda Pharmaceuticals	10.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	No Data
CRON Cronos Group	450	368.54 million	339.80 million	Optionable
PCRX Pacira BioSciences	720	39.86 million	37.31 million	Optionable
VNDA Vanda Pharmaceuticals	290	60.46 million	53.99 million	Optionable

VNDA, CRON, CALT, and PCRX Headlines

Recent News About These Companies

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Consensus Rating of "Moderate Buy" from Brokerages

September 7 at 4:28 AM | marketbeat.com

Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences

September 2, 2026 | prnewswire.com

BlackRock Inc. Makes New Investment in Vanda Pharmaceuticals Inc. $VNDA

September 1, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Invests $1.32 Million in Vanda Pharmaceuticals Inc. $VNDA

August 31, 2026 | marketbeat.com

Ieq Capital LLC Makes New Investment in Vanda Pharmaceuticals Inc. $VNDA

August 26, 2026 | marketbeat.com

Vanda Pharmaceuticals Inc. (VNDA)

August 25, 2026 | finance.yahoo.com

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

August 24, 2026 | prnewswire.com

NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.

August 22, 2026 | prnewswire.com

Monaco Asset Management SAM Invests $1.35 Million in Vanda Pharmaceuticals Inc. $VNDA

August 17, 2026 | marketbeat.com

AIGH Capital Management LLC Purchases New Stake in Vanda Pharmaceuticals Inc. $VNDA

August 17, 2026 | marketbeat.com

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of "Moderate Buy" by Brokerages

August 13, 2026 | marketbeat.com

Vanda (VNDA) Q2 2026 Earnings Call Transcript

August 12, 2026 | finance.yahoo.com

Q3 EPS Estimate for Vanda Pharmaceuticals Cut by Analyst

August 12, 2026 | marketbeat.com

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

August 11, 2026 | zacks.com

Vanda Pharmaceuticals' (VNDA) Buy Rating Reaffirmed at B. Riley Financial

August 10, 2026 | marketbeat.com

Dimensional Fund Advisors LP Lowers Holdings in Vanda Pharmaceuticals Inc. $VNDA

August 9, 2026 | marketbeat.com

Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Vanda Pharmaceuticals Balances Strong Growth With Rising Losses

August 5, 2026 | tipranks.com

Vanda: Q2 Earnings Snapshot

August 5, 2026 | chron.com

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates

August 5, 2026 | zacks.com

Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 5, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VNDA, CRON, CALT, and PCRX Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 09/4/2026

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Cronos Group NASDAQ:CRON

$3.18 -0.08 (-2.45%)

Closing price 04:00 PM Eastern

Extended Trading

$3.19 +0.01 (+0.31%)

As of 07:30 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Pacira BioSciences NASDAQ:PCRX

$25.87 -0.48 (-1.82%)

Closing price 04:00 PM Eastern

Extended Trading

$25.88 +0.01 (+0.04%)

As of 07:38 PM Eastern

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Vanda Pharmaceuticals NASDAQ:VNDA

$5.33 -0.10 (-1.84%)

Closing price 04:00 PM Eastern

Extended Trading

$5.33 0.00 (0.00%)

As of 07:30 PM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VNDA, CRON, CALT, and PCRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VNDA, CRON, CALT, and PCRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VNDA, CRON, CALT, and PCRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VNDA, CRON, CALT, and PCRX Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

Cronos Group NASDAQ:CRON

Pacira BioSciences NASDAQ:PCRX

Vanda Pharmaceuticals NASDAQ:VNDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VNDA, CRON, CALT, and PCRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VNDA, CRON, CALT, and PCRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VNDA, CRON, CALT, and PCRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VNDA, CRON, CALT, and PCRX Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

Cronos Group NASDAQ:CRON

Pacira BioSciences NASDAQ:PCRX

Vanda Pharmaceuticals NASDAQ:VNDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools